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Abstract
Background: Duloxetine and amitriptyline are antidepressants used in the treatment of fibromyalgia. In published
systematic reviews, there is no agreement about which drug is more effective and safer. This study aimed to
compare evidence of the efficacy and safety of duloxetine compared with amitriptyline in the treatment of adult
patients with fibromyalgia. This work contributes to guiding clinicians on the use of duloxetine or amitriptyline for
the treatment of fibromyalgia and provides information for public health decision-makers.
Methods: Overview of systematic reviews of clinical trials comparing duloxetine and amitriptyline in the treatment
of fibromyalgia. The reviews were screened in Cochrane, PubMed, EMBASE, and SRDR with no restrictions on
language and year of publication, considering that the research was conducted in July 2018 and updated until May
2020. The selection was based on the following criteria: adult patients with a diagnosis of fibromyalgia treated with
duloxetine or amitriptyline, comparing the efficacy and safety in pain, fatigue, sleep, and mood disorder symptoms
and quality of life, in addition to the acceptability of these antidepressants. The methodological quality and
strength of evidence were assessed using the AMSTAR and GRADE instruments.
Results: Eight systematic reviews were selected. Amitriptyline had low evidence for pain, moderate evidence for
sleep and fatigue, and high evidence for quality of life. Duloxetine had high quality of evidence in patients with
mood disorders. With low evidence, duloxetine has higher acceptability, but is safer in older patients, while
amitriptyline is safer for non-elderly individuals.
Conclusion: Both antidepressants are effective in the treatment of fibromyalgia, differing according to the patient’s
symptoms and profile.
Registration: PROSPERO: CRD42019116101.
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Background
Fibromyalgia is a syndrome whose etiology is still not fully
understood. It is multifactorial and is characterized by
chronic, widespread, diffuse musculoskeletal pain, often
associated with fatigue, sleep and mood disorders, and a
consequent adverse impact on the quality of life. Its diag-
nosis is very complex, and treatment is multidisciplinary,
which can be pharmacological or not [1]. The global
prevalence of fibromyalgia is 2.7%, ranging from 0.4% in
Greece to 9.3% in Tunisia. Mean prevalence is 3.1% in the
Americas, 2.5% in Europe, and 1.7% in Asia [2]. In Brazil,
a study by Senna et al. [3] recorded a 2.5% prevalence of
the disease, affecting women in more than 90% of cases.
Pharmacotherapy of fibromyalgia can include diverse
therapeutic classes and, among the antidepressants,
there are several studies citing duloxetine hydrochloride
and amitriptyline. Compared to amitriptyline, launched
in 1961, duloxetine is a more recent drug available in
the market, released in 2004, and has in its favor a safety
profile with fewer anticholinergic effects such as dry
mouth, tachycardia, constipation, weight increase, in-
creased intraocular pressure, among others [4].
Systematic reviews are indicating that both duloxetine
and amitriptyline are effective in the treatment of fibro-
myalgia [5, 6]. However, based on individual analysis of
these reviews, one cannot conclude whether these drugs
have the same efficacy and safety in the treatment of the
symptoms of the illness, such as fatigue, sleep, mood dis-
order and quality of life.
When selecting pharmacological therapy, it is relevant
to consider drug cost analysis as part of the final decision.
However, there is a lack of economic studies comparing
antidepressants in fibromyalgia [7]. It is known that the
one-year treatment with duloxetine in the dosages indi-
cated for fibromyalgia is 2.7 times greater than amitriptyl-
ine [8]. In addition, it is important not to neglect patients’
social preferences to support the final decision [9].
This study aimed to synthesize evidence on the effi-
cacy, safety, and acceptability of duloxetine in the treat-
ment of adult patients diagnosed fibromyalgia, compared
with the effects of amitriptyline, based on systematic re-
views of clinical trials.
Methods
Protocol and registration
The research protocol was defined and registered in
the PROSPERO database (registration number
CRD42019116101). The study was reported according
to the initial version of the Preferred Reporting Items
for OoSRs-PRIO-harms [10].
Study design
We conducted an overview of systematic reviews. Over-
view is a method that selects, gathers, and synthesizes
results and improves the accessibility of existing evi-
dence. It is used when there are several systematic re-
views on similar or related topics [11].
Criteria of eligibility
The research question was based on the PICO method.
We included all systematic reviews of clinical trials that
assessed the efficacy and safety of duloxetine and ami-
triptyline to treat fibromyalgia symptoms (pain, fatigue,
sleep and mood disorders, quality of life) and the accept-
ability of these drugs by adult patients with this disease.
Idiom and year of publication were not restricted.
The main outcome of interest was the efficacy of
duloxetine and amitriptyline in the treatment of major
fibromyalgia-related symptoms. The secondary outcomes
were associated with the safety of these drugs, including
adverse responses, and adherence to the treatment
(acceptability).
Search strategy
The reviews were identified in the following databases:
Cochrane Central Register of Controlled Trials, MED-
LINE, EMBASE, and The Systematic Review Data Re-
pository (SRDR). The search was carried out using the
following MeSH (Medical Subject Headings) and DHS
(Descriptors in Health Sciences) terms: (fibromyalgia);
(duloxetine); (amitriptyline); (systematic review). An
additional search strategy was performed in the Episte-
monikos platform, specific for systematic reviews, using
the terms (title:(abstract:(fibromyalgia AND duloxetine
AND amitriptyline AND systematic review)) OR ab-
stract:(abstract:(fibromyalgia AND duloxetine AND ami-
triptyline AND systematic review))). Database searches
were performed in July 2018 and were updated until
May 2020.
Gray literature was also searched in the Sociedade
Médica de Reumatologia [Medical Society of Rheumatol-
ogy] and academic dissertations in Google Scholar
databases.
Selection of studies and data extraction
The titles and abstracts were read by two authors (AF
and LE), who also read the full text of the studies in-
cluded. Afterward, old reviews that had been updated
were excluded, and the latest one was considered. Other
reviews that, when reading, did not meet the eligibility
criteria were also disregarded. The data were extracted
independently by the reviewers. Any disagreements were
resolved by consensus between the two authors or with
the senior researchers (TA and TDP).
General information on the reviews, scoring utilized,
and the outcomes related to pain, sleep, fatigue, quality
of life, acceptability, and safety were collected from the
reviews included.
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Data on reviews were extracted and entered into
Microsoft Excel® datasheets. It was not necessary to con-
tact the selected review’s authors to obtain data.
Assessment of the methodological and evidence quality
The methodological quality of the reviews included in
the overview was assessed by two independent re-
searchers, as recommended by the Cochrane Handbook
for overviews [12], using the Assessment of Multiple
Systematic Reviews – AMSTAR instrument [13]. The re-
sults of the methodological quality assessed in AMSTAR
are rated as “very low quality” (≤ 9 scores), “low quality”
(10–11 scores), “moderate quality” (12–13 scores), and
“high quality” (14–16 scores). The scores resulting from
the assessment of the requirements that were met, as
proposed by the instrument.
The quality of evidence of the reviews included was
assessed according to the Grading of Recommendations
Assessment, Development and Evaluation – GRADE –
[14]. In the case of overviews, the GRADE is adapted as
described in the Cochrane Handbook for Systematic Re-
views of Interventions [12]. We did not re-evaluate each
individual study of the selected reviews. The overview
reviewers assessed and documented the criteria pre-
sented in the reviews included, and descriptively re-
ported the quality of the reviews’ datasets, using the
analysis made by the reviews’ authors. The criteria used
to determine the reduced quality of the evidence were:
risk of bias in the studies included, inconsistency, indir-
ect evidence, imprecision, and publication bias. Due to
subjectivity in the application of the criteria, a calcula-
tion was developed to allow a reproducible attribution of
the GRADE’ s evidence levels. For each outcome, the
above five criteria in the reviews selected were assessed.
The reviewers worked to ensure consensus and
consistency of entering objective data related to these
criteria into a worksheet, and according to the number
of evidence downgrades in the number of reviews that
addressed the outcome, the following rating was used:
0–1.00: not serious; 1.01–1.50: serious; 1.51–2.00: very
serious. This classification was applied to the narrative
table available in the Software GRADE Pro GDT [15]
and was adapted to allow an interpretation of the results,
determining the grading of the evidence found as high,
moderate, low, or very low.
Calculation of overlapping
One of the major challenges of an overview is the over-
lap of studies, that is, when there are individual studies
present in more than one review. We calculated the cor-
rected covered area – CCA, a method that divides the
total number of individual studies by the product be-
tween the number of reviews and the number of non-
repeated studies [16].
Results
A total of 123 abstracts were found, and after exclusion
of those that did not meet the criteria of eligibility, 14
articles remained. One of them [17] was out because it
is not published yet. A total of 13 articles were read in
full. Out of these, five articles were excluded, remaining
eight analyzed reviews [5, 6, 18–23].
Figure 1 is a flowchart of the searches and exclusions.
Table 1 describes the main characteristics of the studies
included, and Table 2 shows the reviews excluded and
justifications.
The methodological qualities of the included reviews
varied largely, as shown in Table 3. Table 4 presents the
assessment of the quality of evidence, according to
GRADE.
Regarding overlapping, the calculation of the area
covered and corrected for this overview indicated 40%
of overlap in individual studies. The result indicates
that there may be duplicates in the systematic re-
views, which may have an impact on data extraction,
because the results of the overlapped studies may in-
fluence the overall analyses of results. For this reason,
a systematic review must be conducted when there
are no reviews with the same objective or when the
existing ones are outdated [16].
Discussion and conclusions
This overview summarized the results of eight sys-
tematic reviews on efficacy, safety and acceptability
of duloxetine in the treatment of adult patients diag-
nosed with fibromyalgia, compared with amitriptyl-
ine. Differences in efficacy varied depending on the
symptom.
Regarding pain, amitriptyline was more effective in
three (37.5%) of the selected reviews [5, 19, 21].
However, the evidence was considered of low quality
in the GRADE analysis, and it should be emphasized
that four reviews [6, 20, 22, 23] did not find a sig-
nificant difference between the two drugs used in
the management of this symptom. Both drugs are
recommended by the European League Against
Rheumatism [24], Sociedade Brasileira de Reumatolo-
gia [1] [Brazilian Society of Rheumatology], and the
Canadian Guidelines for the Diagnosis and Manage-
ment of Fibromyalgia Syndrome [25]. The findings
are consistent with a study [26], which point out
that antidepressants, in general, have not yet shown
quality evidence that they have a significant effect on
pain in fibromyalgia. It would seem that the results
are related to the difficulty of measuring the real
drug-induced potentiation of descending pathways
that inhibit pain in the central nervous system [27].
Regarding the sleep disorders outcome, amitriptyl-
ine was more effective in five (62.5%) of the selected
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reviews [5, 18, 19, 21, 23] with moderate quality of
evidence. Duloxetine did not exhibit proven efficacy
in sleep in any of the reviews. This corroborates the
findings of specific research on sleep disorders in
fibromyalgia [28], which concluded that amitriptyline
is more efficacious than duloxetine for this specific
symptom probably due to its actions on cortical
areas from the central nervous system that regulate
sleep.
Regarding fatigue, six (75%) reviews [5, 18, 19, 21–23]
favored amitriptyline. Duloxetine did not have proven ef-
ficacy for fatigue in any of the reviews examined. The
quality of evidence was considered moderate. However,
fatigue has an extremely complex pathophysiology that
requires a comprehensive approach that goes beyond the
use of antidepressants and it is not possible to explain
the results found definitively.
Regarding mood disorders, 50% of the reviews se-
lected [5, 18, 19, 22] addressed this outcome, and all
of them showed that duloxetine is more efficacious
than amitriptyline in the management of depression-
related symptoms and mood disorders with high qual-
ity of evidence. Therefore, duloxetine would be the
first option when this is the main symptom of pa-
tients with fibromyalgia. A systematic review carried
out in 2016 [29] indicated an average prevalence of
52% of depression in patients with fibromyalgia;
therefore, it is necessary to consider the potentiality
of indication for treatment with duloxetine if a mood
disorder is, in fact, the major symptom. The results
are in agreement with the findings of a study con-
ducted in 2005 [30], which indicated that
fibromyalgia-associated depression will often require
non-selective reuptake inhibitors, such as duloxetine.
Fig. 1 Study flow diagram
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These drugs have fewer adverse reactions than the
tricyclic antidepressants and are much more effective
in the control of depression.
Regarding the quality of life, in two out of five re-
views that addressed this outcome, amitriptyline had
a better result [19, 21]. The evidence was considered
of high quality. However, for the specialists who de-
veloped the Consenso Brasileiro de Fibromialgia [1]
[Brazilian Consensus on Fibromyalgia], both medi-
cines are recommended with the same level of evi-
dence for the management of quality of life. It would
seem that divergence in results occur due to the sub-
jectivity of perception of the quality of life, which, for
many patients, can be directly associated with their
level of pain or in the way pain interferes with the
emotional aspect [31].
Regarding acceptability and safety, the studies
pointed out that was treatments with duloxetine had
less discontinuation of therapy due to adverse
reactions, but amitriptyline was slightly favored re-
garding safety. However, the evidence was considered
of low quality and highlighted that the reviews with
the best quality that addressed safety and acceptabil-
ity [20, 21] did not find significant differences be-
tween both medicines. Both drugs have diverse
adverse reactions, and these outcomes must be con-
sidered with caution, case by case when making a
clinical decision.
It should be noted that according to the American Ge-
riatrics Society [32], there is a strong recommendation
with high quality of evidence against amitriptyline in
older adults, which should be avoided because of its
anticholinergic effect, causing sedation and orthostatic
hypotension. Thus, for older patients, duloxetine would
be the safer choice.
This overview has some limitations. The majority
of the studies were conducted before 2010, before
changes in the fibromyalgia diagnosis criteria, which
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2 4 910 To review evidences of use
of antidepressants in painful
rheumatological conditions
Articles published between
1966 and 2007 in 5
European idioms,
addressing the use of
antidepressants in various
rheumatological conditions,
including FMS. The authors
attributed a rating scale
based on the Jadad
method (0–5), including
studies with scoring above
2
Articles that were scored
below 2 in the Jadad scale
VAS, FIQ,
NRS
aFMS Fibromyalgia, DLX Duloxetine, AMT Amitriptyline, RCT Randomized Clinical Trial, ACR American College of Rheumatology, CWP Chronic Widespread Pain, TCA
Tricyclic Antidepressant, SSRIs Selective Serotonin Reuptake Inhibitor, SNRIs Serotonin and Noradrenaline Reuptake Inhibitor, MAOIs Monoamine Oxidase Inhibitors,
VAS Visual Analog Scale, NPS Numeric Pain Scale, FIQ Fibromyalgia Impact Questionnaire, NNTB Number needed to treat for an additional benefit, NNTH Number
needed to treat to prevent one additional harm, MAF Multidimensional Assessment of Fatigue, MFI Multidimensional Fatigue Inventory, BDI Beck Depression
Inventory, HAM-D Hamilton Depression Scale, BDI Brief Pain Inventory, NRS Numeric Rating Scale, HRQL Health-related Quality of Life
Table 2 Studies excluded for not having met the eligibility criteria
Study excluded Exclusion
code
HÄUSER W, WOLFE F, TÖLLE T, ÜÇEYLER N, SOMMER C. The Role of Antidepressants in the Management of Fibromyalgia Syndrome: A
Systematic Review and Meta-Analysis. CNS Drugs. 2012 Apr; 26 (4):297–307.
4
CHOY E, MARSHALL D, GABRIEL ZL, MITCHELL SA, GYLEE E, DAKIN HA. A Systematic Review and Mixed Treatment Comparison of the
Efficacy of Pharmacological Treatments for Fibromyalgia. Seminars in Arthritis and Rheumatism. 2011 Dec; 41 (3):335–345.e6.
4
SULTAN A, GASKELL H, DERRY S, MOORE RA. Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of
randomised trials. BMC Neurol. 2008 Dec; 8 (1):29.
2
a) Complete articles considered for inclusion, but excluded for not having met the criteria. Exclusion codes: 1 = ineligible outcome, 2 = ineligible intervention, 3 =
ineligible population, 4 = ineligible methodology.
b) The other two papers were old versions of the study of Sommer et al., (2017).
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basically considered palpation of tender points. Some
patients probably were excluded, considering the
new form of diagnosis, which considers the pain
intensity associated with the degree of severity of
other symptoms [33], which could lead to a selection
bias.
There are challenges in common with the routine
of systematic reviews and overviews, such as the
management of large volumes of information and
extracted datasets as well as the time available, re-
sources, and the ability to make consensual decisions
between the authors and reviewers. In the overview
case, we still have the aggravating issue of studies
overlapping, inherent to the level of analysis, which
encompasses systematic reviews and not individual
studies [34].
It was observed that, in some reviews, studies with
amitriptyline are of lower methodological quality
compared with those with duloxetine. This finding
can be explained by the fact that they are older
studies, considering that clinical trials have im-
proved over time, making use of the policy of appli-
cation of trial registration and study assessment
tools [35].
In conclusion, both drugs can be used in the treat-
ment of fibromyalgia, depending on the set of pre-
dominant key symptoms. The results of analyses
indicate recommendation in favor of amitriptyline
with low evidence for pain, moderate evidence for
sleep and fatigue, and high evidence for the quality
of life. Duloxetine is recommended with high quality
of evidence when the patients have mood disorder as
a major symptom, has more acceptability, and is the
first choice for older patients for safety reasons. The
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SR Systematic Review, CT Clinical Trial; a most of the reviews do no detail the results of the heterogeneity tests and, in some of them, the rates were high; b
diverging results with rare approaches to explain heterogeneity; scarce safety data; AMT Amitriptyline, DLX Duloxetine
Table 3 Methodological quality of the systematic reviews
included in the overview
Author, year Methodological quality
(AMSTAR)
Thorpe et al., 2018 [18] 12/16 – moderate
Sommer et al.,2017 [19] 10/16 – low
Smith et al., 2011 [20] 15/16- high
Roskell et al., 2011 [6] 13/16 – moderate
Häuser et al., 2011 [21] 14/16 – high
Häuser et al., 2009 [5] 14/16 – high
Üçeyler et al., 2008 [22] 9/16 – very low
Perrot et al., 2008 [23] 7/16 – very low
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results are aligned with the already-recognized com-
plexity of this disease. This overview contributes to
guiding clinicians and decision-makers in public
health policies based on systematic reviews that ad-
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